ArticleInfection and drug resistance2025
Molecular Characterization and Risk Factors of Carbapenem-Resistant Hypervirulent
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence, mortality, risk factors, and treatment of carbapenem-resistant hypervirulent Klebsiella pneumoniae: an evidence map.Infection · 2026Review
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Virulence and Genomic Profiles of Klebsiella pneumoniae Isolated from Pediatric Patients in Henan, China (2021-2023).Current medical science · 2025Article
- Clinical Characterization, Risk Factors, and Mortality in Patients with Carbapenem-Resistant HypervirulentInfection and drug resistance · 2025Article
- Molecular characteristics and antimicrobial susceptibility of carbapenem-resistantFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Therefore, the objectives of this study were to investigate the prevalence of carbapenem-resistant hypervirulent Methods: Between January 2021 and January 2022, clinically identified carbapenem-resistant Results: In total, 239 CRKp isolates were obtained. The virulence genes with the highest detection rates were Conclusion: Currently, the hospital predominantly carries K64 CR-hvKp that harbors the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.